solrikitug (MK-8226) / Merck (MSD), Uniquity Bio - LARVOL DELTA

In-vitro Characterization of Solrikitug, A Differentiated Anti-TSLP Antibody, Provides Distinct Epitope Binding Profile and Superior Potency Compared to Tezepelumab (ATS 2025) - No abstract available

Preclinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Solrikitug in Healthy Japanese and Non-Japanese Participants (clinicaltrials.gov) - P1 | N=32 | Not yet recruiting | Sponsor: Uniquity One (UNI)

New P1 trial

Differentiated anti-TSLP antibody provides meaningful reductions BAL eosinophils and TARC in the OVA-induced mouse model of asthma (AAAAI-WAO 2025) - "22E5, shows promise as a tool compound to evaluate attenuation of key markers of Type 2 inflammation in a murine asthma model. Solrikitug's enhanced potency over tezepelumab suggests a potential for differentiated efficacy in the treatment of asthma."

Preclinical • Asthma • Immunology • Inflammation • Respiratory Diseases

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults with Eosinophilic Esophagitis (clinicaltrials.gov) - P2 | N=157 | Recruiting | Sponsor: Uniquity One (UNI) | Not yet recruiting ➔ Recruiting

Enrollment open • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis (clinicaltrials.gov) - P2 | N=157 | Not yet recruiting | Sponsor: Uniquity One (UNI)

New P2 trial • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology

A Study to Evaluate Solrikitug in Participants With COPD (ZION) (clinicaltrials.gov) - P2 | N=135 | Recruiting | Sponsor: Uniquity One (UNI) | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

RAINIER: A Study to Evaluate Solriktug in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=84 | Recruiting | Sponsor: Uniquity One (UNI) | Not yet recruiting ➔ Recruiting

Enrollment open • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

RAINIER: A Study to Evaluate Solriktug in Adult Participants With Asthma (clinicaltrials.gov) - P2 | N=84 | Not yet recruiting | Sponsor: Uniquity One (UNI)

New P2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

A Study to Evaluate Solrikitug in Participants With COPD (ZION) (clinicaltrials.gov) - P2 | N=135 | Not yet recruiting | Sponsor: Uniquity One (UNI)

New P2 trial • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Blackstone Life Sciences Launches Uniquity Bio to Develop Novel Medicines in Immunology & Inflammation (Businesswire) - "Blackstone...today announced the launch of the Blackstone Life Sciences ('Blackstone') portfolio company Uniquity Bio...Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug ('IND') application for solrikitug, a monoclonal antibody targeting TSLP, and up to $300 million in capital from Blackstone to advance the asset in multiple indications....In the next month, Uniquity Bio will launch Phase 2 clinical trials in chronic obstructive pulmonary disease ('COPD') — the third leading cause of death worldwide, according to the World Health Organization — and asthma, which the WHO estimates affects more than 260 million people across the globe."

Financing • IND • New P2 trial • Asthma • Chronic Obstructive Pulmonary Disease